Analyst rates Denali (DNLI) stock a Buy. Avlayah's $17.8 million Q3 sales validate its platform, and Q4 guidance of $30-$32 million implies 65%+ sequential growth.
Denali Therapeutics Inc (DNLI) beat Q3 revenue guidance on rapid payer coverage gains and faster patient transitions, guided Q4 to $30--32 million, and ended the quarter with $1.01 billion in cash.
Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +7.25% and +41.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call
Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $34.88, according t
This is the newest page. Registered accounts read further back.